The Swedish specialty pharmaceutical company Pharmalink AB today announced the appointment of Thomas Eklund as new Chairman of the board.
Thomas Eklund joined the board on August 15, 2017.
“We are very happy to have Thomas on board as we prepare for taking our lead candidate drug Nefecon through a clinical Phase 3 study for patients with primary IgA nephropathy. Thomas’s broad knowledge and long experience from both the healthcare industry and the financial sector will be a welcome addition to the team”
said Bengt Julander, founder and outgoing Chairman of Pharmalink.
Thomas has extensive experience from the pharmaceutical and medtech industry, as well as the financial sector where he has held different leading positions, including CEO and Head of Europe at Investor Growth Capital AB. Other previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment AB and Vice President at Handelsbanken Markets. He is currently Chairman of the board of Moberg Pharma AB and Itrim AB, and board member of Boule Diagnostics AB, Biotage AB, Neoventa Medical AB, Memira AB, and Rodebjer Form AB.